Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 190 entries
Sorted by: Best Match Show Resources per page
Thermal boost combined with interstitial brachytherapy in breast conserving therapy - Assessment of early toxicity.

Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology

Chicheł A, Skowronek J, Kanikowski M.
PMID: 24376963
Rep Pract Oncol Radiother. 2011 Apr 08;16(3):87-94. doi: 10.1016/j.rpor.2011.02.004. eCollection 2011.

BACKGROUND: Hyperthermia (HT) causes a direct damage to cancerous cells and/or sensitize them to radiotherapy with usually minimal injury to normal tissues. Adjuvant HT is probably one of the most effective radiation sensitizers known and works best when delivered...

Cite
Chicheł A, Skowronek J, Kanikowski M. Thermal boost combined with interstitial brachytherapy in breast conserving therapy - Assessment of early toxicity. Rep Pract Oncol Radiother. 2011;16(3):87-94doi: 10.1016/j.rpor.2011.02.004.
Chicheł, A., Skowronek, J., & Kanikowski, M. (2011). Thermal boost combined with interstitial brachytherapy in breast conserving therapy - Assessment of early toxicity. Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 16(3), 87-94. https://doi.org/10.1016/j.rpor.2011.02.004
Chicheł, Adam, et al. "Thermal boost combined with interstitial brachytherapy in breast conserving therapy - Assessment of early toxicity." Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology vol. 16,3 (2011): 87-94. doi: https://doi.org/10.1016/j.rpor.2011.02.004
Chicheł A, Skowronek J, Kanikowski M. Thermal boost combined with interstitial brachytherapy in breast conserving therapy - Assessment of early toxicity. Rep Pract Oncol Radiother. 2011 Apr 08;16(3):87-94. doi: 10.1016/j.rpor.2011.02.004. eCollection 2011. PMID: 24376963; PMCID: PMC3863141.
Copy Download .nbib Format: NLM
Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition.

Alzheimer's research & therapy

Selenica ML, Benner L, Housley SB, Manchec B, Lee DC, Nash KR, Kalin J, Bergman JA, Kozikowski A, Gordon MN, Morgan D.
PMID: 24576665
Alzheimers Res Ther. 2014 Feb 27;6(1):12. doi: 10.1186/alzrt241. eCollection 2014.

INTRODUCTION: Tau pathology is associated with a number of age-related neurodegenerative disorders. Few treatments have been demonstrated to diminish the impact of tau pathology in mouse models and none are yet effective in humans. Histone deacetylase 6 (HDAC6) is...

Cite
Selenica ML, Benner L, Housley SB, et al. Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. Alzheimers Res Ther. 2014;6(1):12doi: 10.1186/alzrt241.
Selenica, M. L., Benner, L., Housley, S. B., Manchec, B., Lee, D. C., Nash, K. R., Kalin, J., Bergman, J. A., Kozikowski, A., Gordon, M. N., & Morgan, D. (2014). Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. Alzheimer's research & therapy, 6(1), 12. https://doi.org/10.1186/alzrt241
Selenica, Maj-Linda, et al. "Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition." Alzheimer's research & therapy vol. 6,1 (2014): 12. doi: https://doi.org/10.1186/alzrt241
Selenica ML, Benner L, Housley SB, Manchec B, Lee DC, Nash KR, Kalin J, Bergman JA, Kozikowski A, Gordon MN, Morgan D. Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. Alzheimers Res Ther. 2014 Feb 27;6(1):12. doi: 10.1186/alzrt241. eCollection 2014. PMID: 24576665; PMCID: PMC3978441.
Copy Download .nbib Format: NLM
Late-onset hypogonadism in men with systolic heart failure: prevalence, clinical associates, and impact on long-term survival.

ESC heart failure

Jankowska EA, Tkaczyszyn M, Węgrzynowska-Teodorczyk K, Majda J, von Haehling S, Doehner W, Banasiak W, Anker SD, Ponikowski P.
PMID: 28834667
ESC Heart Fail. 2014 Sep;1(1):41-51. doi: 10.1002/ehf2.12002.

BACKGROUND: Male ageing is characterized by diminished circulating androgens with several adverse psychosomatic consequences and can be aggravated by concomitant chronic diseases. According to the European Male Aging Study (EMAS) Group, late-onset hypogonadism (LOH) refers to testosterone deficiency accompanied...

Cite
Jankowska EA, Tkaczyszyn M, Węgrzynowska-Teodorczyk K, et al. Late-onset hypogonadism in men with systolic heart failure: prevalence, clinical associates, and impact on long-term survival. ESC Heart Fail. 2014;1(1):41-51doi: 10.1002/ehf2.12002.
Jankowska, E. A., Tkaczyszyn, M., Węgrzynowska-Teodorczyk, K., Majda, J., von Haehling, S., Doehner, W., Banasiak, W., Anker, S. D., & Ponikowski, P. (2014). Late-onset hypogonadism in men with systolic heart failure: prevalence, clinical associates, and impact on long-term survival. ESC heart failure, 1(1), 41-51. https://doi.org/10.1002/ehf2.12002
Jankowska, Ewa A, et al. "Late-onset hypogonadism in men with systolic heart failure: prevalence, clinical associates, and impact on long-term survival." ESC heart failure vol. 1,1 (2014): 41-51. doi: https://doi.org/10.1002/ehf2.12002
Jankowska EA, Tkaczyszyn M, Węgrzynowska-Teodorczyk K, Majda J, von Haehling S, Doehner W, Banasiak W, Anker SD, Ponikowski P. Late-onset hypogonadism in men with systolic heart failure: prevalence, clinical associates, and impact on long-term survival. ESC Heart Fail. 2014 Sep;1(1):41-51. doi: 10.1002/ehf2.12002. PMID: 28834667.
Copy Download .nbib Format: NLM
Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure.

Clinical proteomics

Cao TH, Jones DJL, Quinn PA, Chan DCS, Hafid N, Parry HM, Mohan M, Sandhu JK, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Metra M, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zannad F, Zwinderman AH, Voors AA, Lang CC, Ng LL.
PMID: 30410428
Clin Proteomics. 2018 Nov 02;15:35. doi: 10.1186/s12014-018-9213-1. eCollection 2018.

BACKGROUND: Current risk prediction models in heart failure (HF) including clinical characteristics and biomarkers only have moderate predictive value. The aim of this study was to use matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling to determine if...

Cite
Cao TH, Jones DJL, Quinn PA, et al. Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. Clin Proteomics. 2018;15:35doi: 10.1186/s12014-018-9213-1.
Cao, T. H., Jones, D. J. L., Quinn, P. A., Chan, D. C. S., Hafid, N., Parry, H. M., Mohan, M., Sandhu, J. K., Anker, S. D., Cleland, J. G., Dickstein, K., Filippatos, G., Hillege, H. L., Metra, M., Ponikowski, P., Samani, N. J., Van Veldhuisen, D. J., Zannad, F., Zwinderman, A. H., Voors, A. A., Lang, C. C., & Ng, L. L. (2018). Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. Clinical proteomics, 1535. https://doi.org/10.1186/s12014-018-9213-1
Cao, Thong Huy, et al. "Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure." Clinical proteomics vol. 15 (2018): 35. doi: https://doi.org/10.1186/s12014-018-9213-1
Cao TH, Jones DJL, Quinn PA, Chan DCS, Hafid N, Parry HM, Mohan M, Sandhu JK, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Metra M, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zannad F, Zwinderman AH, Voors AA, Lang CC, Ng LL. Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. Clin Proteomics. 2018 Nov 02;15:35. doi: 10.1186/s12014-018-9213-1. eCollection 2018. PMID: 30410428; PMCID: PMC6214161.
Copy Download .nbib Format: NLM
A Telehealth-Delivered Pulmonary Rehabilitation Intervention in Underserved Hispanic and African American Patients With Chronic Obstructive Pulmonary Disease: A Community-Based Participatory Research Approach.

JMIR formative research

Pekmezaris R, Kozikowski A, Pascarelli B, Wolf-Klein G, Boye-Codjoe E, Jacome S, Madera D, Tsang D, Guerrero B, Medina R, Polo J, Williams M, Hajizadeh N.
PMID: 32012039
JMIR Form Res. 2020 Jan 31;4(1):e13197. doi: 10.2196/13197.

BACKGROUND: Although home telemonitoring (TM) is a promising approach for patients managing their chronic disease, rehabilitation using home TM has not been tested for use with individuals living with chronic obstructive pulmonary disease (COPD) residing in underserved communities.OBJECTIVE: This...

Cite
Pekmezaris R, Kozikowski A, Pascarelli B, et al. A Telehealth-Delivered Pulmonary Rehabilitation Intervention in Underserved Hispanic and African American Patients With Chronic Obstructive Pulmonary Disease: A Community-Based Participatory Research Approach. JMIR Form Res. 2020;4(1):e13197doi: 10.2196/13197.
Pekmezaris, R., Kozikowski, A., Pascarelli, B., Wolf-Klein, G., Boye-Codjoe, E., Jacome, S., Madera, D., Tsang, D., Guerrero, B., Medina, R., Polo, J., Williams, M., & Hajizadeh, N. (2020). A Telehealth-Delivered Pulmonary Rehabilitation Intervention in Underserved Hispanic and African American Patients With Chronic Obstructive Pulmonary Disease: A Community-Based Participatory Research Approach. JMIR formative research, 4(1), e13197. https://doi.org/10.2196/13197
Pekmezaris, Renee, et al. "A Telehealth-Delivered Pulmonary Rehabilitation Intervention in Underserved Hispanic and African American Patients With Chronic Obstructive Pulmonary Disease: A Community-Based Participatory Research Approach." JMIR formative research vol. 4,1 (2020): e13197. doi: https://doi.org/10.2196/13197
Pekmezaris R, Kozikowski A, Pascarelli B, Wolf-Klein G, Boye-Codjoe E, Jacome S, Madera D, Tsang D, Guerrero B, Medina R, Polo J, Williams M, Hajizadeh N. A Telehealth-Delivered Pulmonary Rehabilitation Intervention in Underserved Hispanic and African American Patients With Chronic Obstructive Pulmonary Disease: A Community-Based Participatory Research Approach. JMIR Form Res. 2020 Jan 31;4(1):e13197. doi: 10.2196/13197. PMID: 32012039; PMCID: PMC7055744.
Copy Download .nbib Format: NLM
Erratum to: Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.

Clinical research in cardiology : official journal of the German Cardiac Society

Filippatos G, Farmakis D, Metra M, Cotter G, Davison BA, Felker GM, Greenberg BH, Hua TA, Pang PS, Ponikowski P, Qian M, Severin TA, Voors AA, Teerlink JR.
PMID: 28752374
Clin Res Cardiol. 2017 Nov;106(11):938. doi: 10.1007/s00392-017-1139-5.

No abstract available.

Cite
Filippatos G, Farmakis D, Metra M, et al. Erratum to: Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. Clin Res Cardiol. 2017;106(11):938doi: 10.1007/s00392-017-1139-5.
Filippatos, G., Farmakis, D., Metra, M., Cotter, G., Davison, B. A., Felker, G. M., Greenberg, B. H., Hua, T. A., Pang, P. S., Ponikowski, P., Qian, M., Severin, T. A., Voors, A. A., & Teerlink, J. R. (2017). Erratum to: Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. Clinical research in cardiology : official journal of the German Cardiac Society, 106(11), 938. https://doi.org/10.1007/s00392-017-1139-5
Filippatos, Gerasimos, et al. "Erratum to: Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial." Clinical research in cardiology : official journal of the German Cardiac Society vol. 106,11 (2017): 938. doi: https://doi.org/10.1007/s00392-017-1139-5
Filippatos G, Farmakis D, Metra M, Cotter G, Davison BA, Felker GM, Greenberg BH, Hua TA, Pang PS, Ponikowski P, Qian M, Severin TA, Voors AA, Teerlink JR. Erratum to: Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. Clin Res Cardiol. 2017 Nov;106(11):938. doi: 10.1007/s00392-017-1139-5. PMID: 28752374; PMCID: PMC6828441.
Copy Download .nbib Format: NLM
'WhatsApp.

Clinical kidney journal

Jhaveri KD, Pascarelli B, Hasan A, Kozikowski A, Fishbane S, Pekmezaris R.
PMID: 32082548
Clin Kidney J. 2019 Apr 30;13(1):8-13. doi: 10.1093/ckj/sfz045. eCollection 2020 Feb.

BACKGROUND: Teaching methods in most residency and fellowship programs have not yet addressed the challenges of rapid dissemination of new scientific information. Our Northwell nephrology fellowship program used the smartphone application WhatsAppMETHODS: A WhatsAppRESULTS: Faculty feedback was generally positive....

Cite
Jhaveri KD, Pascarelli B, Hasan A, et al. 'WhatsApp. Clin Kidney J. 2019;13(1):8-13doi: 10.1093/ckj/sfz045.
Jhaveri, K. D., Pascarelli, B., Hasan, A., Kozikowski, A., Fishbane, S., & Pekmezaris, R. (2020). 'WhatsApp. Clinical kidney journal, 13(1), 8-13. https://doi.org/10.1093/ckj/sfz045
Jhaveri, Kenar D, et al. "'WhatsApp." Clinical kidney journal vol. 13,1 (2020): 8-13. doi: https://doi.org/10.1093/ckj/sfz045
Jhaveri KD, Pascarelli B, Hasan A, Kozikowski A, Fishbane S, Pekmezaris R. 'WhatsApp. Clin Kidney J. 2019 Apr 30;13(1):8-13. doi: 10.1093/ckj/sfz045. eCollection 2020 Feb. PMID: 32082548; PMCID: PMC7025336.
Copy Download .nbib Format: NLM
Iron deficiency as an emerging therapeutic target in patients stabilized after an episode of acute heart failure.

Cardiology journal

Tkaczyszyn M, Skrzypczak T, Michałowicz J, Ponikowski P, Jankowska EA.
PMID: 34897633
Cardiol J. 2021;28(6):962-969. doi: 10.5603/CJ.a2021.0165. Epub 2021 Dec 13.

Acute heart failure (AHF) syndromes are among the most frequent causes of hospitalization in the elderly and put a heavy financial burden on healthcare systems, mainly due to high early readmission rates. The understanding of AHF has evolved over...

Cite
Tkaczyszyn M, Skrzypczak T, Michałowicz J, et al. Iron deficiency as an emerging therapeutic target in patients stabilized after an episode of acute heart failure. Cardiol J. 2021;28(6):962-969doi: 10.5603/CJ.a2021.0165.
Tkaczyszyn, M., Skrzypczak, T., Michałowicz, J., Ponikowski, P., & Jankowska, E. A. (2021). Iron deficiency as an emerging therapeutic target in patients stabilized after an episode of acute heart failure. Cardiology journal, 28(6), 962-969. https://doi.org/10.5603/CJ.a2021.0165
Tkaczyszyn, Michał, et al. "Iron deficiency as an emerging therapeutic target in patients stabilized after an episode of acute heart failure." Cardiology journal vol. 28,6 (2021): 962-969. doi: https://doi.org/10.5603/CJ.a2021.0165
Tkaczyszyn M, Skrzypczak T, Michałowicz J, Ponikowski P, Jankowska EA. Iron deficiency as an emerging therapeutic target in patients stabilized after an episode of acute heart failure. Cardiol J. 2021;28(6):962-969. doi: 10.5603/CJ.a2021.0165. Epub 2021 Dec 13. PMID: 34897633.
Copy Download .nbib Format: NLM
HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community.

ESC heart failure

Ben Avraham B, Crespo-Leiro MG, Filippatos G, Gotsman I, Seferovic P, Hasin T, Potena L, Milicic D, Coats AJS, Rosano G, Ruschitzka F, Metra M, Anker S, Altenberger J, Adamopoulos S, Barac YD, Chioncel O, De Jonge N, Elliston J, Frigeiro M, Goncalvesova E, Grupper A, Hamdan R, Hammer Y, Hill L, Itzhaki Ben Zadok O, Abuhazira M, Lavee J, Mullens W, Nalbantgil S, Piepoli MF, Ponikowski P, Ristic A, Ruhparwar A, Shaul A, Tops LF, Tsui S, Winnik S, Jaarsma T, Gustafsson F, Ben Gal T.
PMID: 34519177
ESC Heart Fail. 2021 Dec;8(6):4394-4408. doi: 10.1002/ehf2.13588. Epub 2021 Sep 14.

The accepted use of left ventricular assist device (LVAD) technology as a good alternative for the treatment of patients with advanced heart failure together with the improved survival of the LVAD-supported patients on the device and the scarcity of...

Cite
Ben Avraham B, Crespo-Leiro MG, Filippatos G, et al. HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community. ESC Heart Fail. 2021;8(6):4394-4408doi: 10.1002/ehf2.13588.
Ben Avraham, B., Crespo-Leiro, M. G., Filippatos, G., Gotsman, I., Seferovic, P., Hasin, T., Potena, L., Milicic, D., Coats, A. J. S., Rosano, G., Ruschitzka, F., Metra, M., Anker, S., Altenberger, J., Adamopoulos, S., Barac, Y. D., Chioncel, O., De Jonge, N., Elliston, J., Frigeiro, M., Goncalvesova, E., Grupper, A., Hamdan, R., Hammer, Y., Hill, L., Itzhaki Ben Zadok, O., Abuhazira, M., Lavee, J., Mullens, W., Nalbantgil, S., Piepoli, M. F., Ponikowski, P., Ristic, A., Ruhparwar, A., Shaul, A., Tops, L. F., Tsui, S., Winnik, S., Jaarsma, T., Gustafsson, F., & Ben Gal, T. (2021). HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community. ESC heart failure, 8(6), 4394-4408. https://doi.org/10.1002/ehf2.13588
Ben Avraham, Binyamin, et al. "HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community." ESC heart failure vol. 8,6 (2021): 4394-4408. doi: https://doi.org/10.1002/ehf2.13588
Ben Avraham B, Crespo-Leiro MG, Filippatos G, Gotsman I, Seferovic P, Hasin T, Potena L, Milicic D, Coats AJS, Rosano G, Ruschitzka F, Metra M, Anker S, Altenberger J, Adamopoulos S, Barac YD, Chioncel O, De Jonge N, Elliston J, Frigeiro M, Goncalvesova E, Grupper A, Hamdan R, Hammer Y, Hill L, Itzhaki Ben Zadok O, Abuhazira M, Lavee J, Mullens W, Nalbantgil S, Piepoli MF, Ponikowski P, Ristic A, Ruhparwar A, Shaul A, Tops LF, Tsui S, Winnik S, Jaarsma T, Gustafsson F, Ben Gal T. HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community. ESC Heart Fail. 2021 Dec;8(6):4394-4408. doi: 10.1002/ehf2.13588. Epub 2021 Sep 14. PMID: 34519177; PMCID: PMC8712781.
Copy Download .nbib Format: NLM
Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.

JAMA cardiology

Docherty KF, Jhund PS, Claggett B, Ferreira JP, Bengtsson O, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, McMurray JJV.
PMID: 34319398
JAMA Cardiol. 2021 Nov 01;6(11):1298-1305. doi: 10.1001/jamacardio.2021.2632.

IMPORTANCE: Sodium glucose cotransporter 2 inhibitors reduce morbidity and mortality in patients with heart failure and reduced ejection fraction (HFrEF). Clinicians may find estimates of the projected long-term benefits of sodium glucose cotransporter 2 inhibitors a helpful addition to...

Cite
Docherty KF, Jhund PS, Claggett B, et al. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. JAMA Cardiol. 2021;6(11):1298-1305doi: 10.1001/jamacardio.2021.2632.
Docherty, K. F., Jhund, P. S., Claggett, B., Ferreira, J. P., Bengtsson, O., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Sjöstrand, M., Solomon, S. D., McMurray, J. J. V. (2021). Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. JAMA cardiology, 6(11), 1298-1305. https://doi.org/10.1001/jamacardio.2021.2632
Docherty, Kieran F, et al. "Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial." JAMA cardiology vol. 6,11 (2021): 1298-1305. doi: https://doi.org/10.1001/jamacardio.2021.2632
Docherty KF, Jhund PS, Claggett B, Ferreira JP, Bengtsson O, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, McMurray JJV. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. JAMA Cardiol. 2021 Nov 01;6(11):1298-1305. doi: 10.1001/jamacardio.2021.2632. PMID: 34319398; PMCID: PMC8576587.
Copy Download .nbib Format: NLM
Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical treatment in heart failure with reduced ejection fraction.

European journal of heart failure

SeferoviĆ PM, Polovina M, Adlbrecht C, BĚlohlávek J, Chioncel O, Goncalvesová E, MilinkoviĆ I, Grupper A, Halmosi R, Kamzola G, Koskinas KC, Lopatin Y, Parkhomenko A, Põder P, RistiĆ AD, Šakalyt G, TrbušiĆ M, Tundybayeva M, Vrtovec B, Yotov YT, MiličiĆ D, Ponikowski P, Metra M, Rosano G, Coats AJ.
PMID: 34755422
Eur J Heart Fail. 2021 Nov 09; doi: 10.1002/ejhf.2378. Epub 2021 Nov 09.

Guideline-directed medical therapy (GDMT) has the potential to reduce the risks of mortality and hospitalisation in patients with heart failure (HF) with reduced ejection fraction (HFrEF). However, real-world data indicate that many patients with HFrEF do not receive optimised...

Cite
SeferoviĆ PM, Polovina M, Adlbrecht C, et al. Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical treatment in heart failure with reduced ejection fraction. Eur J Heart Fail. 2021;doi: 10.1002/ejhf.2378.
SeferoviĆ, P. M., Polovina, M., Adlbrecht, C., BĚlohlávek, J., Chioncel, O., Goncalvesová, E., MilinkoviĆ, I., Grupper, A., Halmosi, R., Kamzola, G., Koskinas, K. C., Lopatin, Y., Parkhomenko, A., Põder, P., RistiĆ, A. D., Šakalyt, G., TrbušiĆ, M., Tundybayeva, M., Vrtovec, B., Yotov, Y. T., MiličiĆ, D., Ponikowski, P., Metra, M., Rosano, G., & Coats, A. J. (2021). Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical treatment in heart failure with reduced ejection fraction. European journal of heart failure, . https://doi.org/10.1002/ejhf.2378
SeferoviĆ, Petar M, et al. "Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical treatment in heart failure with reduced ejection fraction." European journal of heart failure vol. (2021). doi: https://doi.org/10.1002/ejhf.2378
SeferoviĆ PM, Polovina M, Adlbrecht C, BĚlohlávek J, Chioncel O, Goncalvesová E, MilinkoviĆ I, Grupper A, Halmosi R, Kamzola G, Koskinas KC, Lopatin Y, Parkhomenko A, Põder P, RistiĆ AD, Šakalyt G, TrbušiĆ M, Tundybayeva M, Vrtovec B, Yotov YT, MiličiĆ D, Ponikowski P, Metra M, Rosano G, Coats AJ. Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical treatment in heart failure with reduced ejection fraction. Eur J Heart Fail. 2021 Nov 09; doi: 10.1002/ejhf.2378. Epub 2021 Nov 09. PMID: 34755422.
Copy Download .nbib Format: NLM
Viscoelastic Polyurethane Foams with Reduced Flammability and Cytotoxicity.

Materials (Basel, Switzerland)

Okrasa M, Leszczyńska M, Sałasińska K, Szczepkowski L, Kozikowski P, Nowak A, Szulc J, Adamus-Włodarczyk A, Gloc M, Majchrzycka K, Ryszkowska J.
PMID: 35009298
Materials (Basel). 2021 Dec 26;15(1). doi: 10.3390/ma15010151.

Consistent and proper use of respiratory protective devices (RPD) is one of the essential actions that can be taken to reduce the risk of exposure to airborne hazards, i.e., biological and nonbiological aerosols, vapours, and gases. Proper fit of...

Cite
Okrasa M, Leszczyńska M, Sałasińska K, et al. Viscoelastic Polyurethane Foams with Reduced Flammability and Cytotoxicity. Materials (Basel). 2021;15(1)doi: 10.3390/ma15010151.
Okrasa, M., Leszczyńska, M., Sałasińska, K., Szczepkowski, L., Kozikowski, P., Nowak, A., Szulc, J., Adamus-Włodarczyk, A., Gloc, M., Majchrzycka, K., & Ryszkowska, J. (2021). Viscoelastic Polyurethane Foams with Reduced Flammability and Cytotoxicity. Materials (Basel, Switzerland), 15(1), . https://doi.org/10.3390/ma15010151
Okrasa, Małgorzata, et al. "Viscoelastic Polyurethane Foams with Reduced Flammability and Cytotoxicity." Materials (Basel, Switzerland) vol. 15,1 (2021). doi: https://doi.org/10.3390/ma15010151
Okrasa M, Leszczyńska M, Sałasińska K, Szczepkowski L, Kozikowski P, Nowak A, Szulc J, Adamus-Włodarczyk A, Gloc M, Majchrzycka K, Ryszkowska J. Viscoelastic Polyurethane Foams with Reduced Flammability and Cytotoxicity. Materials (Basel). 2021 Dec 26;15(1). doi: 10.3390/ma15010151. PMID: 35009298; PMCID: PMC8746040.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 190 entries